TY - JOUR
T1 - Implications of fetoplacental mosaicism on cell-free DNA testing for sex chromosome aneuploidies
AU - Grati, Francesca Romana
AU - Bajaj, Komal
AU - Zanatta, Valentina
AU - Malvestiti, Francesca
AU - Malvestiti, Barbara
AU - Marcato, Livia
AU - Grimi, Beatrice
AU - Maggi, Federico
AU - Simoni, Giuseppe
AU - Gross, Susan J.
AU - Ferreira, Jose
N1 - Publisher Copyright:
© 2017 John Wiley & Sons, Ltd.
PY - 2017/10
Y1 - 2017/10
N2 - Objective: The unique biological behavior of sex chromosomes has implications for cell-free DNA (cfDNA) testing. Our purpose is to predict the (1) false positive/negative rates of cfDNA testing consequent to fetoplacental mosaicism for any sex chromosome aneuploidies (SCA) and (2) positive predictive value (PPV) and negative predictive values of a high-risk and low-risk cfDNA result for any SCA. Method: This is a retrospective analysis of 67 030 chorionic villus sampling karyotypes, including fetoplacental mosaicism cases. Results: Non-mosaic 45, X is associated with cystic hygroma/increased nuchal translucency and fetal anomalies. The false positive rate consequent to confined placental mosaicism is predicted to be 0.05%. The estimated false negative rate is in the range of 0% to 5.7% for all non-mosaic SCAs; it is 70% for mosaic 45, X with normal ultrasound. The predicted PPV on amniocytes is very high for most SCAs (94.4–99.4%). However, the stratified analysis shows that the PPV is much lower for 45, X without ultrasound anomalies compared with 45, X with abnormal scan (51% or 71%, vs 99%, respectively). Conclusion: Mosaicism is a major issue for SCA cfDNA testing, and prenatal confirmation, preferentially with amniocentesis if there are no ultrasound anomalies, remains important in counseling. As PPV varies on the basis of the presence of an ultrasound anomaly, skilled evaluation is critical.
AB - Objective: The unique biological behavior of sex chromosomes has implications for cell-free DNA (cfDNA) testing. Our purpose is to predict the (1) false positive/negative rates of cfDNA testing consequent to fetoplacental mosaicism for any sex chromosome aneuploidies (SCA) and (2) positive predictive value (PPV) and negative predictive values of a high-risk and low-risk cfDNA result for any SCA. Method: This is a retrospective analysis of 67 030 chorionic villus sampling karyotypes, including fetoplacental mosaicism cases. Results: Non-mosaic 45, X is associated with cystic hygroma/increased nuchal translucency and fetal anomalies. The false positive rate consequent to confined placental mosaicism is predicted to be 0.05%. The estimated false negative rate is in the range of 0% to 5.7% for all non-mosaic SCAs; it is 70% for mosaic 45, X with normal ultrasound. The predicted PPV on amniocytes is very high for most SCAs (94.4–99.4%). However, the stratified analysis shows that the PPV is much lower for 45, X without ultrasound anomalies compared with 45, X with abnormal scan (51% or 71%, vs 99%, respectively). Conclusion: Mosaicism is a major issue for SCA cfDNA testing, and prenatal confirmation, preferentially with amniocentesis if there are no ultrasound anomalies, remains important in counseling. As PPV varies on the basis of the presence of an ultrasound anomaly, skilled evaluation is critical.
UR - http://www.scopus.com/inward/record.url?scp=85028943430&partnerID=8YFLogxK
U2 - 10.1002/pd.5138
DO - 10.1002/pd.5138
M3 - Article
C2 - 28801976
AN - SCOPUS:85028943430
SN - 0197-3851
VL - 37
SP - 1017
EP - 1027
JO - Prenatal Diagnosis
JF - Prenatal Diagnosis
IS - 10
ER -